Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancerKentaro Tanaka, Kumiko Isse, Tomomichi Fujihira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
EphB2 is a prognostic factor in colorectal cancerAdrian M Jubb, Fiona Zhong, Sheila Bheddah, et al.
Cancer Research|October 20, 2004
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomasDavid Dornan, Sheila Bheddah, Kim Newton, et al.
Plos One|May 9, 2015
Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspiratesWade C Anderson, Michael B Boyd, Jorge Aguilar, et al.
Cancer Research|May 19, 2007
Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor modelsYoujun Chen, Suzanna Clark, Terence Wong, et al.
Plos One|July 30, 2011
Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signalingMarinella G Callow, Hoanh Tran, Lilian Phu, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 7, 2011
Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidneyDolores Diaz, Krishna Allamneni, Jacqueline M Tarrant, et al.
Oncotarget|November 2, 2017
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapiesRobert J Cardnell, Lerong Li, Triparna Sen, et al.
Cancer Research|May 11, 2017
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung CancerSai Kiran Sharma, Jacob Pourat, Dalya Abdel-Atti, et al.
The Lancet. Oncology|December 10, 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyCharles M Rudin, M Catherine Pietanza, Todd M Bauer, et al.
Pageof 2